Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Fulcrum Therapeutics, Inc. - Common Stock (FULC) Institutional Ownership
CUSIP: 359616109
13F Institutional Holders and Ownership History from Q3 2019 to Q1 2026
Institutions Reporting
172
Shares (Excl. Options)
67,444,422
Price
$11.31
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- FULC on Nasdaq
- Shares outstanding
- 67,171,444
- Price per share
- $7.67
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 67,444,422
- Total reported value
- $762,744,178
- % of total 13F portfolios
- 0%
- Share change
- +11,821,898
- Value change
- +$134,984,797
- Number of holders
- 172
- Price from insider filings
- $7.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- FULC - Fulcrum Therapeutics, Inc. - Common Stock is tracked under CUSIP 359616109.
- 172 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 172 to 7 between Q4 2025 and Q1 2026.
- Reported value moved from $762,744,178 to $276,517.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 172 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 359616109?
CUSIP 359616109 identifies FULC - Fulcrum Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue With The Right Next Step
- Latest 13F filings - identify new institutional portfolio moves.
- Latest Schedule 13D/13G reports - cross-check beneficial ownership events.
- All institutional ownership pages - compare nearby CUSIPs and holder concentration.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 359616109:
Significant Owners of Fulcrum Therapeutics, Inc. - Common Stock (FULC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | -12% | $67,231,227 | +$6,025,691 | 6,649,973 | +9.8% | RA Capital Management, L.P. | 31 Dec 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.4% | +52% | $18,495,988 | +$6,069,154 | 5,067,394 | +49% | SUVRETTA CAPITAL MANAGEMENT, LLC | 31 Mar 2025 |
| Nantahala Capital Management, LLC | 7.7% | $17,439,379 | 4,777,912 | Nantahala Capital Management, LLC | 30 Sep 2024 | |||
| BlackRock, Inc. | 6% | -19% | $30,090,560 | -$7,016,336 | 3,270,322 | -19% | BlackRock, Inc. | 30 Sep 2025 |
| Adage Capital Management, L.P. | 4.5% | -44% | $22,374,400 | -$19,844,400 | 2,432,000 | -47% | Adage Capital Management, L.P. | 30 Sep 2025 |
As of 31 Dec 2025, 172 institutional investors reported holding 67,444,422 shares of Fulcrum Therapeutics, Inc. - Common Stock (FULC). This represents 100% of the company’s total 67,171,444 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Fulcrum Therapeutics, Inc. - Common Stock (FULC) together control 85% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.8% | 6,561,111 | +22% | 1.8% | $74,206,165 |
| RA CAPITAL MANAGEMENT, L.P. | 9% | 6,053,960 | -41% | 0.7% | $68,470,288 |
| TCG Crossover Management, LLC | 7.8% | 5,250,000 | 0% | 2% | $59,377,500 |
| Nantahala Capital Management, LLC | 6.4% | 4,293,346 | -8.1% | 2.9% | $48,557,743 |
| BlackRock, Inc. | 6.3% | 4,263,761 | +15% | 0% | $48,223,137 |
| VANGUARD GROUP INC | 5.3% | 3,559,552 | +19% | 0% | $40,258,533 |
| BRAIDWELL LP | 4.6% | 3,061,222 | +1295% | 1.1% | $34,622,421 |
| Point72 Asset Management, L.P. | 3.6% | 2,398,232 | 0.04% | $27,124,004 | |
| Siren, L.L.C. | 2.9% | 1,950,000 | 0.66% | $22,054,500 | |
| D. E. Shaw & Co., Inc. | 2.8% | 1,913,755 | +32% | 0.02% | $21,644,569 |
| First Turn Management, LLC | 2.8% | 1,892,683 | 2.4% | $21,406,245 | |
| GSK plc | 2.7% | 1,785,714 | 0% | 2.5% | $20,196,425 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.5% | 1,700,000 | -30% | 0.03% | $19,227,000 |
| Ikarian Capital, LLC | 2% | 1,375,472 | +6.7% | 2% | $15,556,588 |
| Aberdeen Group plc | 1.9% | 1,254,027 | +809% | 0.02% | $14,183,045 |
| ADAR1 Capital Management, LLC | 1.9% | 1,253,749 | +267% | 1.1% | $14,179,901 |
| CITADEL ADVISORS LLC | 1.8% | 1,207,004 | +41% | 0.01% | $13,651,216 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,105,813 | +10% | 0% | $12,509,702 |
| DIMENSIONAL FUND ADVISORS LP | 1.6% | 1,051,124 | -19% | 0% | $11,888,372 |
| STATE STREET CORP | 1.5% | 1,005,345 | -5.4% | 0% | $11,370,452 |
| Balyasny Asset Management L.P. | 1.4% | 970,439 | -33% | 0.02% | $10,975,665 |
| Vestal Point Capital, LP | 1.4% | 950,000 | 0.39% | $10,744,500 | |
| GREAT POINT PARTNERS LLC | 1.2% | 800,000 | 2.9% | $9,048,000 | |
| ACADIAN ASSET MANAGEMENT LLC | 1.1% | 736,740 | +36% | 0.01% | $8,326,000 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.87% | 582,377 | +52% | 0.02% | $6,586,684 |
Institutional Holders of Fulcrum Therapeutics, Inc. - Common Stock (FULC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 36,111 | $276,517 | -$983 | $7.67 | 7 |
| 2025 Q4 | 67,444,422 | $762,744,178 | +$134,984,797 | $11.31 | 172 |
| 2025 Q3 | 53,790,538 | $494,909,349 | -$1,273,053 | $9.20 | 127 |
| 2025 Q2 | 54,400,644 | $374,498,177 | +$23,533,452 | $6.88 | 122 |
| 2025 Q1 | 51,307,184 | $147,764,693 | -$3,070,431 | $2.88 | 115 |
| 2024 Q4 | 51,666,381 | $242,831,448 | -$8,308,464 | $4.70 | 117 |
| 2024 Q3 | 54,857,560 | $195,845,950 | -$86,380,213 | $3.57 | 127 |
| 2024 Q2 | 64,752,304 | $401,470,762 | +$19,716,085 | $6.20 | 120 |
| 2024 Q1 | 60,342,845 | $569,639,654 | -$2,974,963 | $9.44 | 122 |
| 2023 Q4 | 61,083,723 | $412,326,970 | +$14,153,071 | $6.75 | 100 |
| 2023 Q3 | 56,394,454 | $250,394,156 | +$9,019,379 | $4.44 | 79 |
| 2023 Q2 | 55,518,138 | $183,197,485 | -$14,257,183 | $3.30 | 85 |
| 2023 Q1 | 60,413,854 | $172,155,022 | +$51,602 | $2.85 | 115 |
| 2022 Q4 | 50,644,890 | $368,693,025 | -$13,010,376 | $7.28 | 109 |
| 2022 Q3 | 52,209,184 | $422,360,458 | +$98,764,326 | $8.09 | 104 |
| 2022 Q2 | 40,127,745 | $196,621,873 | -$32,729,118 | $4.90 | 97 |
| 2022 Q1 | 39,071,704 | $923,864,555 | +$64,674,079 | $23.65 | 104 |
| 2021 Q4 | 37,197,291 | $657,236,909 | -$42,835,792 | $17.69 | 107 |
| 2021 Q3 | 36,552,286 | $1,031,536,477 | +$305,128,643 | $28.21 | 100 |
| 2021 Q2 | 26,798,436 | $280,833,000 | -$3,275,840 | $10.48 | 66 |
| 2021 Q1 | 26,913,060 | $317,031,000 | +$45,552,581 | $11.78 | 68 |
| 2020 Q4 | 22,170,825 | $259,615,000 | +$20,231,071 | $11.71 | 65 |
| 2020 Q3 | 20,593,739 | $163,306,000 | -$36,882,837 | $7.93 | 53 |
| 2020 Q2 | 20,455,938 | $373,550,782 | +$66,390,720 | $18.29 | 60 |
| 2020 Q1 | 16,827,383 | $200,921,119 | +$11,941,010 | $11.94 | 46 |
| 2019 Q4 | 15,784,835 | $262,061,000 | +$1,373,802 | $16.64 | 38 |
| 2019 Q3 | 15,905,791 | $105,135,052 | +$105,135,052 | $6.64 | 39 |